Novavax grabs another CFO while Pat Cotroneo retires from FibroGen; Eli Lilly reassembles key staff after biomedicines unit split
→ The perennial Charlie Brown of vaccine development, Novavax is grappling with Lucy’s knack for pulling the football away once again, this time with its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
